This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
Community health workers (CHWs) serve as a very important direct link between patients, communities and health services. As trusted on-the-ground support to community members, they therefore expand access to essential healthcare information as well as available treatment and prevention programmes.
...
This course book provides appropriate, cost-effective, and sustainable targeted learning for the large numbers of emerging community health workers in South Africa.
more
What have we learned about COVID-19 and antibiotics so far? What happens when antibiotics are not taken according to prescription or are used irrationally? When are antibiotics prescribed in the course of COVID-19 treatment? Professor Hanan H. Balkhy explains in Science in 5 this week.
Este documento incluye los resultados de un proceso de elaboración rápida de guías. La información incluida en esta guía refleja la evidencia a la fecha publicada en el documento. Las recomendaciones se basaron en la evidencia disponible y su calidad (metodología GRADE) en el momento en que s...e publicó la guía. Sin embargo, reconociendo que hay numerosas investigaciones en curso, la Organización Panamericana de la Salud actualizará de forma periódica estas revisiones y las recomendaciones correspondientes.
more
People with asthma (PWA) generally are considered at higher risk from respiratory infections, as is seen annually with influenza. At the outset of the COVID-19 pandemic, PWA were widely assumed to be at increased risk from COVID-19. However, as data emerged throughout 2020, the association between a...sthma and COVID-19 appeared less clear.
more
Änderung gegenüber der Version vom 26.1.2021: Aktualisierung der Informationen über monoklonale Antikörper und Rekonvaleszentenplasma
Uso de doxiciclina para prevenção e tratamento de pacientes com Covid-19
23 February 2021
This document describes the medical devices required for the clinical management of COVID-19, selected and prioritized according to the latest available evidence and interim guidelines. This includes: oxygen therapy, pulse oximeters, patient monitors, thermometers, infusion and suc...tion pumps, X-ray, ultrasound and CT scanners as well as personal protective equipment. In order to facilitate access to quality assured priority medical devices, the document also includes technical and performance characteristics, related standards, accessories and consumables. It is intended for policy-makers and planning officers in Ministries of Health, procurement and regulatory agencies, intergovernmental and international agencies as well as the medical device industry.
This document is an update to the List of priority medical devices for COVID-19 case management and Technical specifications for invasive and non-invasive ventilators for COVID-19.
This document complements the Technical specifications of personal protective equipment for COVID-19.
more
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
Note d’information scientifique, 17 juin 2021
The sixth course of the Clinical Management of Patients with COVID-19 course series is devoted to the rehabilitation of patients with COVID-19. The seven course modules address the manifold and varied rehabilitation needs of patients recovering from COVID-19, including patients with cognitive impair...ment, physical deconditioning and weakness, respiratory impairment, swallow impairment, communication impairment and challenges in completing Activities of Daily Living (ADLs). Techniques for rehabilitation also are addressed
more
6a edición clínica. Nuevo: 4. Vacunas (26 de abril); Nuevo: 5. Pruebas y procedimientos de diagnóstico (7 de abril); Nuevo: 7. COVID-19 persistente (7 de abril)
Настоящее руководство «Клиническое ведение случаев COVID-19» базируется на
вышеуказанных стратегических приоритетах и адресовано клиницистам, участвующим в
оказа...ии помощи пациентам с подозреваемой или подтвержденной инфекцией COVID-19.
Оно не предназначено для того, чтобы заменить индивидуальное клиническое суждение или
консультацию специалиста, но призвано помочь клиническим работникам в обеспечении
наиболее эффективного ведения случаев. Повышенное внимание в настоящем руководстве
уделяется вопросам, касающимся особых и уязвимых групп населения, таких как дети,
пожилые люди и беременные женщины.
Interim guidance on clinical management COVID-19
more
Esta primeira versão de Medicamentos para prevenção da COVID-19: Orientação dinâmica da OMS aborda o uso de hidroxicloroquina para prevenção da COVID-19. Segue-se a publicação de uma análise sistemática e NMA que reuniu dados de seis estudos com 6.059 participantes que não tinham COVID-...19 e receberam hidroxicloroquina. Três estudos envolveram participantes que tiveram uma exposição conhecida a uma pessoa com infecção por SARS-CoV-2. Em resposta à divulgação dos dados de estudos, o GDG da OMS desenvolveu recomendações sobre a hidroxicloroquina, um agente anti-inflamatório que atua por meio do bloqueio dos receptores Toll-like, reduzindo a ativação das células dendríticas. É usada para tratar a artrite reumatoide e o lúpus eritematoso sistêmico. Tem um efeito antiviral contra muitos vírus in vitro, inclusive o SARS-CoV-2, mas não foi demonstrado um efeito antiviral clinicamente útil para nenhuma infecção viral.
more
Вариативные рекомендации 24 сентября 2021 г.
Этот документ представляет собой текущие рекомендации ВОЗ. В них будут вноситься изменения и дополнения,
касающиеся нов...ых средств для лечения COVID-19, в том числе гидроксихлорохина и комбинации лопинавира и
ритонавира . Размещение, распространение и обновление данных рекомендаций происходит в приложении
MAGICapp, а их формат и структура обеспечивают для пользователей удобство работы и поиска. Реализована
функция постоянного обновления информации, относящейся к действующим положениям, которая позволяет
знакомиться с новыми данными наряду с актуальными рекомендациями. В разделе 4 описаны основные
методологические аспекты процедуры составления вариативных рекомендаций.
more